Brief: Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd
17/11/2025 13:17
Silo Pharma Inc SILO.O: SILO PHARMA PARTNERS WITH ALLUCENT TO SUPPORT PLANNED FDA INVESTIGATIONAL NEW DRUG APPLICATION FOR SPC-15 AS A THERAPEUTIC FOR PTSD SILO PHARMA INC - EXPECTS IND SUBMISSION IN 2026 AND FIH TRIAL POST FDA APPROVAL SILO PHARMA INC - DATA FROM GLP-COMPLIANT TOXICOLOGY STUDY EXPECTED IN EARLY 2026 Source text: ID:nGNX65fKBQ Further company coverage: SILO.O
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement